Literature DB >> 33613528

Outcome Predictors of Biopsy-Proven Myeloperoxidase-Anti-Neutrophil Cytoplasmic Antibody-Associated Glomerulonephritis.

Yifei Ge1, Guang Yang1, Xiangbao Yu1, Bin Sun1, Bo Zhang1, Yanggang Yuan1, Ming Zeng1, Ningning Wang1, Huijuan Mao1, Changying Xing1.   

Abstract

Objective: To determine the prognostic values of histopathologic classification of myeloperoxidase-anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis and other clinical and laboratory features at the time of presentation on renal and patient survival associated with myeloperoxidase-ANCA-associated glomerulonephritis (MPO-ANCA-GN).
Methods: A total of 112 patients diagnosed with MPO-ANCA-GN from October 2005 to December 2018 were enrolled. The baseline clinical characteristics, renal histopathological data, and risk factors predictive of renal and patient survival were retrospectively analyzed.
Results: All 112 patients underwent renal biopsy. Disease in 32 patients was classified as focal, 26 as mixed, 29 as crescentic, and 25 as sclerotic. Over a median follow-up period of 41.5 months, there were 44 patients dialysis-dependent. The renal survival rate was significantly higher in the focal group than the other groups (p < 0.001) and significantly lower in the sclerotic group (p < 0.05). In addition, disease histopathologically classified as sclerotic (p = 0.044), high serum creatinine level (≥320 μmol/L, p < 0.001), low albumin (<30 g/L, p = 0.024) and hemoglobin level (<90 g/L, p = 0.044) were associated with a greater risk of ESRD. After follow-up, 70 (62.5%) of 112 patients survived. Old age (≥60 years, p = 0.018) and low serum albumin (<30 g/L, p = 0.006) was significant risk factor for patient survival.
Conclusion: Among patients with MPO-ANCA-GN, those with poor renal function, disease histopathologically classified as sclerotic, and lower albumin and hemoglobin levels were risk factors for ESRD, while older age and low serum albumin level were associated with a greater risk for all-cause mortality.
Copyright © 2021 Ge, Yang, Yu, Sun, Zhang, Yuan, Zeng, Wang, Mao and Xing.

Entities:  

Keywords:  histopathologic classification; myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated glomerulonephritis; patient survival; renal survival; vasculitis

Year:  2021        PMID: 33613528      PMCID: PMC7889806          DOI: 10.3389/fimmu.2020.607261

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  39 in total

1.  Prognostic Value of Histologic Classification of ANCA-Associated Glomerulonephritis.

Authors:  Rune Bjørneklett; Sanjeevan Sriskandarajah; Leif Bostad
Journal:  Clin J Am Soc Nephrol       Date:  2016-10-18       Impact factor: 8.237

Review 2.  The Prevalence and Management of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in China.

Authors:  Zhi-Ying Li; Tian-Tian Ma; Min Chen; Ming-Hui Zhao
Journal:  Kidney Dis (Basel)       Date:  2015-12-09

Review 3.  Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study.

Authors:  Anthony D Booth; Mike K Almond; Aine Burns; Peter Ellis; Gill Gaskin; Guy H Neild; Martin Plaisance; Charles D Pusey; David R W Jayne
Journal:  Am J Kidney Dis       Date:  2003-04       Impact factor: 8.860

4.  Estimating glomerular filtration rate from serum creatinine and cystatin C.

Authors:  Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey
Journal:  N Engl J Med       Date:  2012-07-05       Impact factor: 91.245

5.  Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission in Nonlife-Threatening Relapses of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Randomized, Controlled Trial.

Authors:  Janneke Tuin; Patricia M Stassen; Daria I Bogdan; Jan Broekroelofs; Pieter van Paassen; Jan Willem Cohen Tervaert; Jan-Stephan Sanders; Coen A Stegeman
Journal:  Clin J Am Soc Nephrol       Date:  2019-06-28       Impact factor: 8.237

6.  Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement.

Authors:  Weixin Hu; Chunbei Liu; Honglang Xie; Huiping Chen; Zhihong Liu; Leishi Li
Journal:  Nephrol Dial Transplant       Date:  2007-12-08       Impact factor: 5.992

7.  Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.

Authors:  R A Luqmani; P A Bacon; R J Moots; B A Janssen; A Pall; P Emery; C Savage; D Adu
Journal:  QJM       Date:  1994-11

8.  Clinical outcomes of Japanese MPO-ANCA-related nephritis: significance of initial renal death for survival.

Authors:  Kimio Watanabe; Yoshihiro Tani; Hiroshi Kimura; Kenichi Tanaka; Yoshimitsu Hayashi; Koichi Asahi; Keiji Sato; Mamoru Sato; Masato Matsushima; Masaaki Nakayama; Tsuyoshi Watanabe
Journal:  Intern Med       Date:  2012-08-01       Impact factor: 1.271

Review 9.  Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis.

Authors:  Marc Hilhorst; Pieter van Paassen; Jan Willem Cohen Tervaert
Journal:  J Am Soc Nephrol       Date:  2015-05-08       Impact factor: 10.121

10.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Authors:  J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts
Journal:  Arthritis Rheum       Date:  2013-01
View more
  4 in total

1.  Meta-Analytical Accuracy of ANCA Renal Risk Score for Prediction of Renal Outcome in Patients With ANCA-Associated Glomerulonephritis.

Authors:  Mengdi Xia; Ruiran Yu; Zaiqiong Zheng; Huan Li; Jie Feng; Xisheng Xie; Dongming Chen
Journal:  Front Med (Lausanne)       Date:  2022-01-06

2.  Assessment of Renal Risk Score and Histopathological Classification for Prediction of End-Stage Kidney Disease and Factors Associated With Change in eGFR After ANCA-Glomerulonephritis Diagnosis.

Authors:  Benoit Brilland; Charlotte Boud'hors; Marie-Christine Copin; Pierre Jourdain; Nicolas Henry; Samuel Wacrenier; Assia Djema; Clément Samoreau; Jean-Philippe Coindre; Maud Cousin; Jeremie Riou; Anne Croue; Jean-Paul Saint-André; Jean-François Subra; Giorgina Barbara Piccoli; Jean-François Augusto
Journal:  Front Immunol       Date:  2022-03-22       Impact factor: 7.561

3.  Relationship Between Gender and 1-Year Mortality in ANCA-Associated Vasculitis Patients: A Single-Center Retrospective Analysis and Meta-Analysis.

Authors:  Qing Zhu; Fen Li; Xi Xie; Bilin Chen; Qianwen Yu; Yusong Wei; Yan Ge
Journal:  Front Med (Lausanne)       Date:  2022-07-13

4.  Commentary: Outcome Predictors of Biopsy-Proven Myeloperoxidase-Anti-Neutrophil Cytoplasmic Antibody-Associated Glomerulonephritis.

Authors:  Samuel Wacrenier; Charlotte Boud'hors; Giorgina Piccoli; Jean-François Augusto; Benoit Brilland
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.